pneumonia
respiratori
infect
account
high
morbid
young
old
individu
weaken
immun
system
fri
et
al
addit
presenc
chronic
underli
condit
contribut
mark
increas
pneumonia
risk
age
jackson
et
al
fri
et
al
common
pneumonia
commun
acquir
pneumonia
cap
musher
thorner
caus
bacteria
virus
less
commonli
fungi
microorgan
mayoclin
unlik
hospitalacquir
pneumonia
acquir
hospit
diseas
cap
also
acquir
nonhospit
individu
pneumonia
haemophilu
influenza
staphylococcu
aureu
influenza
viru
pulmonari
diseas
includ
lung
cancer
main
caus
agent
pneumonia
pseudomona
aeruginosa
pneumocysti
jirovecii
moraxella
catarrhali
gramneg
bacteria
less
common
caus
agent
musher
thorner
prior
use
antibiot
pneumonia
case
caus
pneumonia
musher
thorner
howev
recent
studi
reveal
pneumonia
case
unit
state
us
caus
pneumonia
restrepo
et
al
jain
et
al
wherea
countri
pneumonia
respons
higher
proport
case
musher
thorner
gadsbi
et
al
pneumonia
show
high
incid
rate
hospit
patient
older
outpati
men
age
jackson
et
al
addit
variou
risk
factor
pneumonia
includ
smoke
diabet
heart
failur
lung
cancer
renal
diseas
copd
viral
infect
exampl
cap
incid
rate
coincid
influenza
viru
epidem
carvalho
et
al
sheng
et
al
nation
statist
data
also
show
cap
pattern
close
reflect
tempor
pattern
death
percentag
attribut
pneumonia
influenza
us
jackson
et
al
mani
pneumonia
treatment
avail
antibiot
breath
treatment
oxygen
therapi
korsgaard
et
al
van
der
poll
opal
howev
peopl
weak
immun
system
like
complic
respiratori
failur
uncontrol
inflamm
ie
sepsi
lung
abscess
cdc
addit
emerg
antibiot
resist
strain
consid
seriou
problem
kaplan
mason
picazo
thu
prevent
pneumonia
occurr
vaccin
import
inde
pneumococc
vaccin
season
flu
vaccin
recommend
children
adult
ksid
pneumococc
vaccin
commerci
avail
sinc
use
reduc
burden
pneumococc
diseas
among
children
elderli
moreov
declin
cap
caus
pneumococcu
us
due
univers
pneumococc
vaccin
adult
children
musher
thu
advisori
committe
immun
practic
acip
recommend
pneumococc
vaccin
immunocompromis
adult
kim
et
al
robinson
et
al
prevent
pneumonia
pneumonia
gram
posit
bacterium
serotyp
kalin
recent
serotyp
identifi
kapatai
et
al
pneumonia
known
common
caus
cap
steel
et
al
bewick
et
al
caus
agent
pneumococc
diseas
otiti
media
mening
bacteremia
bogaert
et
al
pneumonia
colon
nasopharynx
asymptomat
one
lead
caus
high
mortal
morbid
infant
elderli
immunocompromis
peopl
black
et
al
wunderink
water
specif
serotyp
may
colon
nasopharynx
becom
preval
depend
invas
indirectli
reflect
epidemiolog
chang
flasch
et
al
pneumonia
mani
virul
factor
could
contribut
colon
develop
pneumococc
diseas
kadioglu
et
al
bacteri
host
factor
contribut
colon
defin
anim
model
kadioglu
et
al
mous
acut
pneumonia
model
pneumolysin
pli
essenti
factor
bacteri
surviv
respiratori
tract
kadioglu
et
al
virul
factor
pspa
lyta
psaa
piaa
nana
also
play
lead
role
respiratori
tract
infect
pneumonia
kadioglu
et
al
pneumolysin
cytolyt
toxin
wellknown
virul
factor
pneumonia
function
tolllik
receptor
ligand
activ
complement
pathway
stimul
variou
inflammatori
cytokin
hirst
et
al
lyta
also
known
autolysin
digest
cell
wall
releas
pneumolysin
cellular
content
van
der
poll
opal
moreov
inhibit
convertas
format
andr
et
al
psaa
pneumococc
surfac
antigen
involv
metal
ion
uptak
lead
protect
oxid
stress
kadioglu
et
al
piaa
pneumococc
iron
acquisit
anoth
compon
atpbind
cassett
transport
system
involv
acquisit
iron
bacteri
growth
van
der
poll
opal
final
nana
neuraminidas
also
known
sialidas
cleav
termin
sialic
acid
promot
adhes
colon
kadioglu
et
al
molecul
also
deglycosyl
complement
compon
evad
host
complement
pathway
andr
et
al
influenza
viru
respiratori
syncyti
viru
parainfluenza
viru
adenoviru
coronaviru
commonli
detect
patient
cap
may
unclear
extent
organ
caus
diseas
predispos
patient
secondari
bacteri
infect
johnston
et
al
pavia
influenza
viru
serial
infect
bacteria
lethal
increas
mina
klugman
exampl
pneumococc
coinfect
respons
high
mortal
pandem
monsalvo
et
al
moreov
report
influenza
viru
coinfect
compris
cap
case
michelow
et
al
although
influenza
viru
pneumococcu
coinfect
respons
higher
mortal
morbid
current
pneumococc
conjug
vaccin
provid
suffici
protect
serial
coinfect
model
metzger
et
al
therefor
develop
new
type
vaccin
protect
influenza
viru
pneumococcu
coinfect
requir
pneumococc
vaccin
divid
whole
cell
vaccin
subunit
whole
cell
vaccin
includ
live
attenu
vaccin
inactiv
vaccin
subunit
vaccin
includ
polysaccharid
vaccin
conjug
vaccin
protein
base
vaccin
commerci
avail
pneumococc
vaccin
belong
subunit
vaccin
avail
pneumococc
vaccin
marker
recent
pediatr
pneumococc
diseas
incid
alreadi
success
reduc
introduct
conjug
pneumococc
vaccin
vilacorcol
ochoagondar
howev
current
pneumococc
vaccin
usag
increas
preval
pneumococc
diseas
induc
serotyp
includ
vaccin
flanneri
et
al
croucher
et
al
addit
pneumococc
diseas
elderli
remain
consider
burden
despit
vaccin
thu
immun
vaccin
recommend
elderli
hayward
et
al
overcom
disadvantag
vaccin
tabl
inde
combin
current
pneumococc
vaccin
produc
superior
immun
respons
alon
reason
acip
recommend
serial
vaccin
elderli
sinc
kobayashi
et
al
therefor
new
potenti
vaccin
effect
protect
pneumonia
investig
tabl
undergo
clinic
trial
tabl
attenu
weaken
form
pathogen
use
vaccin
current
avail
live
vaccin
cost
effect
minor
rare
case
live
attenu
vaccin
strain
revert
virul
wild
type
caus
sever
diseas
pliaka
et
al
howev
whole
cell
vaccin
superior
provid
protect
variou
pneumococc
serotyp
demonstr
live
attenu
mucos
vaccin
wu
et
al
roch
et
al
kim
et
al
inactiv
vaccin
made
treat
pathogen
chemic
physic
process
compar
live
attenu
vaccin
inactiv
vaccin
safer
mcconnel
pachon
inactiv
whole
cell
vaccin
could
confer
effect
protect
lethal
pneumococc
challeng
demonstr
reduc
colon
higher
surviv
rate
choi
et
al
moffitt
et
al
hvalby
et
al
polysaccharid
capsul
encapsul
bacteria
major
virul
factor
use
antigen
howev
polysaccharid
antigen
interact
b
cell
directli
induc
antibodi
product
without
cell
respons
goldblatt
song
et
al
infant
particularli
immatur
b
cell
respons
vaccin
also
induc
cell
respons
provid
adequ
protect
pneumococc
infect
simon
et
al
pneumococc
polysaccharid
vaccin
pneumovax
compris
polysaccharid
serotyp
respons
invas
pneumococc
infect
world
effect
invas
pneumococc
diseas
ipd
recommend
individu
age
children
age
fedson
guppi
howev
prevent
incid
pneumonia
morbid
huss
et
al
sinc
elicit
serum
igg
secretori
iga
nasopharynx
although
strong
evid
cap
prevent
avail
seem
allevi
cap
sever
kraicermelam
et
al
johnston
et
al
vaccin
use
polysaccharid
antigen
conjug
carrier
protein
goldblatt
contrast
polysaccharid
vaccin
conjug
vaccin
elicit
cell
respons
result
superior
immunogen
song
et
al
immun
last
longer
goldblatt
pneumococc
conjug
vaccin
valent
capsular
polysaccharid
includ
serotyp
compris
serotyp
serotyp
ad
prevnar
shown
induc
protect
effect
ipd
pneumonia
otiti
media
lee
et
al
pilishvili
et
al
moreov
could
protect
hivinfect
adult
pneumococc
infect
french
et
al
markedli
decreas
pneumococc
pneumonia
incid
children
pneumococc
serotyp
respons
half
childhood
pneumococc
pneumonia
case
olart
et
al
vaccin
recommend
infant
children
adult
vaccin
consist
purifi
protein
antigen
produc
bacteria
nascimento
leit
protein
antigen
elicit
antibodi
vaccin
person
thu
protect
diseas
variou
recombin
protein
vaccin
develop
elicit
suffici
protect
immun
respons
tabl
respiratori
pathogen
initi
colon
mucos
surfac
caus
diseas
therefor
mucos
immun
system
play
import
role
primari
physic
barrier
protect
respiratori
diseas
neutra
kozlowski
holmgren
czerkinski
mucos
immun
system
secretori
iga
key
factor
mucos
immun
induc
vaccin
entrap
microb
block
microbi
adher
invas
lamm
hutch
et
al
local
igg
also
induc
kozlowski
et
al
thu
mucos
vaccin
induc
mucos
system
immun
respons
provid
effect
protect
respiratori
diseas
pneumonia
compar
mucos
vaccin
inject
vaccin
less
effect
gener
mucos
immun
respons
lamm
could
transmit
infect
via
blood
contamin
needl
levin
dougan
despit
mucos
vaccin
advantag
use
diseas
cholera
polio
influenza
vaccin
avail
holmgren
czerkinski
mucos
immun
system
react
mucos
vaccin
microorgan
make
implement
difficult
ie
mucos
vaccin
adher
mucos
surfac
subject
degrad
proteas
nucleas
trigger
immun
respons
real
pathogen
thu
feasibl
mucos
vaccin
must
overcom
hurdl
evok
secretori
immun
respons
secretori
iga
common
pneumonia
cap
mainli
caus
pneumonia
although
antibiot
use
treat
pneumonia
incid
antibiot
resist
increas
risk
pneumonia
children
elderli
weak
immun
respons
high
thu
prevent
pneumonia
ipd
includ
sepsi
acip
recommend
vaccin
moreov
influenza
viru
critic
factor
increas
pneumococc
pneumonia
risk
link
higher
mortal
introduct
pcv
vaccin
incid
pneumonia
ipd
greatli
decreas
howev
current
vaccin
prevent
emerg
pneumococc
diseas
caus
serotyp
includ
vaccin
thu
develop
new
mucos
vaccin
type
need
protect
broader
rang
serotyp
